The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly understood. Here, using a genetically inducible model of KRAS loss of heterozygosity (LOH), we show that KRAS dimerization mediates wild-type KRAS-dependent fitness of human and murine KRAS mutant LUAD tumor cells and underlies resistance to MEK inhibition. These effects are abrogated when wild-type KRAS is replaced by KRAS D154Q , a mutant that disrupts dimerization at the a4-a5 KRAS dimer interface without changing other fundamental biochemical properties of KRAS, both in vitro and in vivo. Moreover, dimerization has a critical role in the oncogenic activity of mutant KRAS. Our studies provide mechanistic and biological insights into the role of KRAS dimerization and highlight a role for disruption of dimerization as a therapeutic strategy for KRAS mutant cancers.
INTRODUCTION
Mutations in the KRAS gene are the most frequent RAS mutations detected in human cancer, and they are the prevalent driver oncogenes in many cancers, including lung adenocarcinomas (LUADs) (Miller and Miller, 2012) . There are no effective targeted therapies for lung cancers driven by KRAS-activating mutations, and these patients are almost exclusively treated with standardof-care chemotherapy (Wood et al., 2016) . Small-molecule compounds targeting the MAPK pathway-one of the most prominent KRAS downstream mediators-have been developed (Zhao and Adjei, 2014) ; however, they show minimal clinical efficacy in KRAS mutant LUAD either as single agents or in combination with chemotherapy (Blumenschein et al., 2015; Jä nne et al., 2017) . This applies to both MEK and ERK inhibitors (Kö hler et al., 2017) , and in vitro evidence suggests that the lack of clinical efficacy is due to a combination of narrow therapeutic windows, the genetic context, relief of feedback inhibition on upstream kinases, and intrinsic resistance (Samatar and Poulikakos, 2014) . Hence, the need to develop new therapeutic approaches for the treatment of KRAS mutant lung cancer remains urgent. Several alternative strategies for inhibiting druggable targets in KRAS mutant LUAD have been recently proposed in preclinical models and are in various stages of clinical development (Ambrogio et al., 2016; Castellano et al., 2013; Kim et al., 2016; Manchado et al., 2016; Ostrem et al., 2013; Zhu et al., 2014) .
It has been known for several years that wild-type KRAS acts as a tumor suppressor in KRAS mutant cancer cells (Singh et al., 2005) . These tumor-growth-restraining functions in LUAD are bypassed when the wild-type KRAS allele is lost during tumor progression (To et al., 2008; Zhang et al., 2001 ). Alternatively, wildtype KRAS inhibitory effects can also be overcome by copy number gains of the oncogenic form, resulting in allelic imbalance (Westcott et al., 2015) . Furthermore, loss of wild-type KRAS has recently been shown to enhance tumor fitness in KRAS mutant acute myeloid leukemia (AML) and colorectal cancer (CRC) cell lines while concomitantly resulting in increased sensitivity to MEK inhibition (Burgess et al., 2017) . How wild-type KRAS exerts its growth-inhibitory function is still largely unknown. Proposed molecular mechanisms include competition for proper membrane localization, shared regulators, downstream mediators, or activation of parallel signaling pathways (Young et al., 2013) .
Numerous observations suggest that RAS functions as a dimer (Gü ldenhaupt et al., 2012; Lin et al., 2014; Muratcioglu et al., 2015; Spencer-Smith et al., 2017; Zhou and Hancock, 2015) . Additionally, activation of RAF-a known RAS effector-requires RAF dimerization, which may be facilitated by RAS dimerization (Lavoie and Therrien, 2015) . Indeed, artificially forced dimerization of RAS has been shown to enhance activation of the MAPK pathway (Nan et al., 2015) . However, definitive proof that dimerization of RAS is essential for its biological functions is lacking.
Here, we demonstrate a critical role for KRAS dimerization by studying a dimerization-deficient D154Q mutant. We show that a dimerization-deficient wild-type KRAS is no longer able to impart a growth-inhibitory effect on mutant KRAS or alter the therapeutic index to MEK inhibitors. Furthermore, we demonstrate the requirement of dimerization to sustain the oncogenic function of mutant KRAS. Collectively, our studies uncover new insights into KRAS biology and reveal disruption of dimerization as a mice 6 months after AdCRE (scale bar: 500mm). See also Figure S1 .
potential therapeutic strategy that may be effective in KRAS mutant cancers.
RESULTS

Loss of Wild-Type KRas Accelerates Cell Proliferation and Increases Mutant KRAS-GTP Levels
In Vitro and In Vivo To study the impact of wild-type KRAS on oncogenic KRAS, we used an inducible system generated from Ras-less mouse embryonic fibroblasts (MEFs) (Drosten et al., 2010 Figure 1C ).
To investigate the contribution of wild-type KRas expression in vivo, we used a mouse model that allows selective deletion of the wild-type KRas allele in lung epithelial cells expressing the mutant KRas oncogene (Puyol et al., 2010) . In this model, the wild-type KRas allele is replaced by a conditional KRas lox allele in KRas +/LSLG12V mice (Guerra et al., 2003) ( Figure S1D ). In- expression, those mice also expressing the wild-type KRas allele had a median survival of 40 weeks ( Figure 1D ). Histological analysis of KRas lox/LSLG12V mice 6 months following AdCRE infection revealed increased tumor number and size compared to KRas +/LSLG12V mice ( Figure 1E ), as previously reported (Puyol et al., 2010) .
Wild-Type KRas Impairs Response to MEK Inhibition in KRAS Mutant Cells
Responses of KRAS mutant cancer cells (Solit et al., 2006) and human tumors (Blumenschein et al., 2015; Jä nne et al., 2017) to MEK inhibitor treatment are variable, and the contingencies are unclear. However, our model system is ideally suited to ask whether the presence of wild-type KRAS contributes to MEK inhibitor sensitivity in KRAS mutant lung cancer. Ablation of wild-type KRas alleles by 4OHT dramatically increased sensitivity of KRas lox KRAS MUT cells to the MEK1/2 inhibitor selumetinib ( Figure 2A ). Wild-type KRas allele loss also increased sensitivity to trametinib, a more potent FDA-approved drug with superior pharmacological properties due to its ability to prevent feedback reactivation of ERK (Lito et al., 2014) (Figure 2A Figure S2B ).
Charge-Reversal D154Q Mutation Impairs KRAS Dimerization Prior evidence in support of RAS dimerization led us to speculate that the genetic interactions we observed between wildtype and mutant KRAS could be explained on the basis of physical, RAS dimer interactions. To test this hypothesis, we sought to identify a KRAS mutation that could efficiently disrupt KRAS dimers. We evaluated KRAS crystal structures that we and others had previously solved (Hunter et al., 2014 (Hunter et al., , 2015 Xiong et al., 2016) , searching for those with crystal packing interactions meeting criteria we considered important for biologically relevant dimer formation. These included (1) positioning of C termini of both dimer members in the same direction as would be expected for simultaneous insertion of prenylated CAAX motifs into the cell membrane, (2) positioning of the GNP nucleotide binding pocket toward the center of the cell to maximally expose the pocket toward the cellular store of the GNP nucleotide where exchange would be most efficient, and (3) an overall configuration that would allow binding of KRAS effectors simultaneously to both dimerized KRAS protomers without significant steric clashes. Interestingly, in our crystal structure of wild-type KRAS bound to GTP, we noted an interaction involving the a4-a5 interface meeting these conditions ( Figure S3A ). Of note, this model shared the same interface compared to a model wherein HRAS crystal structures were used to identify a4-a5 as the dimer interface (Spencer-Smith et al., 2017) and is also consistent with biophysical measurements evaluating NRAS dimerization (Gü ldenhaupt et al., 2012) . In this model, residue D154 forms a salt bridge with R161 from the opposing monomer. We thus hypothesized that a charge-reversal mutation in this residue (D154Q) could potentially lead to disruption of dimerization by repulsion at the interface.
To directly test this hypothesis, we designed a cell-based FRET system using CFP (donor) and YFP (acceptor) fusions of KRAS to measure protein-protein interactions between KRAS dimers ( Figures S3B-S3D double-charge reversal mutation was able to restore dimerization ( Figures 3B and S3G ). These effects were not related to alterations in protein expression ( Figure S3E ).
Collectively, these data demonstrate that KRAS dimerizes in cells through the a4-a5 interface in an EGF-/mitogendependent manner utilizing a salt bridge between D154 and R161.
To exclude the possibility that D154Q alters the biochemical properties (and therefore the activation state) of KRAS, we Figure S4C ). We further evaluated whether D154Q could change the ability of KRAS to engage with CRAF, a requirement for activation of KRAS-dependent MAPK signaling (Lavoie and Therrien, 2015) . We first tested the interaction between recombinant KRAS proteins with CRAF using a quantitative protein-protein interaction assay we previously reported (Hunter et al., 2015) . KRAS D154Q exhibited similar RAF-RBD binding affinity to KRAS WT . Of note, we observed similar findings when we compared KRAS G12D to KRAS G12D/D154Q ( Figure S4D ). In addition, we conducted fluorescence resonance energy transfer (FRET) experiments to examine KRAS-CRAF interactions. We co-transfected HEK293T cells with CFP-KRAS WT or CFP-KRAS D154Q in combination with YFP-CRAF. Under conditions of serum supplementation or EGF stimulation, but not serum starvation, we observed an increase in CFP signal after YFP bleaching for both KRAS WT -and KRAS D154Q -expressing cells, suggesting a protein-protein interaction between KRAS and CRAF (Figures 3C and S4E) . Consistent with the FRET results, we further noted that KRAS WT and KRAS D154Q recruited CRAF from the cytosol to the plasma membrane upon serum supplementation (Figure S4E ). Together, our observations support the conclusion that KRAS D154Q does not impair the interaction between KRAS and CRAF and that KRAS dimerization is not required for CRAF-KRAS interactions.
Finally, we evaluated whether oncogenic mutations might impact KRAS dimerization. We introduced the D154Q mutation in cis with either G12C or G12D mutants fused to CFP or YFP. Similar to wild-type, KRAS G12C and KRAS G12D showed increased CFP signal after YFP bleach, consistent with dimer formation upon serum stimulation, but not in the presence of D154Q ( Figures 3D and S4F ). D154Q had no impact on GTP hydrolysis in KRAS G12D ( Figure S4A ). Collectively, these data show that D154Q abrogates both wild-type and mutant KRAS dimerization without influencing intrinsic GTPase activity, GEF or GAP sensitivity, or CRAF binding. 4D , and S5E). Recent studies suggest that robust MAPK pathway suppression, with >80%-90% inhibition of ERK signaling, must be achieved in order to obtain therapeutic efficacy (Albeck et al., 2013; Chapman et al., 2014) . Therefore, we considered that the residual MAPK activity attributable to the wild-type KRAS allele Figure S5E and data not shown). Error bars represent mean ± SD (p < 0.001; unpaired Student's t test). See also Figure S5 and Figure S6B) and increased the IC 50 of MEK inhibitors ( Figure S6C ). Figure 5A ). Consistently, evaluation of a six-gene signature of ERK-regulated genes recently developed to predict benefit from MEK inhibition in KRAS mutant lung cancer cells (Brant et al., 2017 ) demonstrated a significant downregulation following selumetinib treatment in both parental and KRAS D154Q -expressing KRas
G12V
;p53 À/À tumors, but not tumors expressing KRAS WT ( Figure S6E ).
To extend the in vivo analysis to human cancer, we generated nude mice xenografts from A549 or H2122 cells expressing either KRAS WT or KRAS D154Q and compared mutants, including membrane localization, binding to downstream mediators (Figures 3, S3 , and S4), or total amount of KRAS-GTP, which was similar in the presence or absence of the D154Q mutation ( Figure 6B ).
Because RAF activation by KRAS requires RAF dimerization (Lavoie and Therrien, 2015) , and each RAF monomer has the potential to bind KRAS ( Figure 3C and Figure 6C ). This is in agreement with recent findings describing that disrupted RAS dimerization and nanoclustering (using a monobody) led to blockade of CRAF/BRAF heterodimerization (Spencer-Smith et al., 2017 cells were completely unable to form tumors in vivo (Figure 7A ). Histology and immunostains revealed that large tumors Figure 7C ). Consistently, the expression of ERK transcriptional target genes was significantly decreased in KRas lox KRAS MUT/D154Q tumors ( Figure 7D ), demonstrating an impairment of the activation of the MAPK pathway when oncogenic KRAS is forced to function as a monomer in vivo.
DISCUSSION
Here, we demonstrate that KRAS dimerization is critical to several previously observed but poorly understood KRAS activities. Wild-type KRAS antagonizes oncogenic KRAS, resulting in inefficient cellular transformation and reduced tumor burden in several malignancies (Burgess et al., 2017; To et al., 2008; Zhang et al., 2001) . We demonstrate that the molecular basis for the inhibitory effects of wild-type KRAS is dimerization with mutant KRAS. In addition, we show that dimerization is required for the function of oncogenic KRAS mutants. Altogether, this body of work adds KRAS dimerization as an essential feature of KRAS function to the two previously well-established requirements, GTP loading and membrane localization, and furthermore demonstrates that these requirements are interrelated.
This study adds the importance of an intact a4-a5 KRAS interface to prior observations suggesting various dimer dependencies, including GTP-binding and membrane association (Muratcioglu et al., 2015; Nan et al., 2015) . Although suggestive, these studies did not definitively prove whether naturally occurring KRAS dimers play an essential role in the onset and/or regulation of signaling dynamics. Using a cell-based FRET system, we demonstrate increased KRAS dimerization under conditions that influence the fraction of GTP-bound KRAS (Figure 3) . It should be emphasized that the current findings are consistent with prior studies by Nan and colleagues suggesting that membrane localization contributes to formation of KRAS dimers and/or nanoclusters (Nan et al., 2015) . Indeed, we would expect that that membrane association would be necessary to create a high-enough local concentration of KRAS in the proper orientation to enable the relatively weak protein-protein interaction at the a4-a5 interface.
These findings may have implications for biomarker-driven treatment of patients with tumors bearing KRAS mutations. At the biological level, the presence of wild-type KRAS shifts the therapeutic index for MEK inhibition (Figures 2 and 5) . MEK inhibitors have demonstrated limited efficacy in patients with KRAS mutant lung cancer (Blumenschein et al., 2015; Jä nne et al., 2017) . Although several mechanisms may account for these findings, our observations suggest that patients with KRAS mutant LUAD are more likely to benefit from MEK inhibitors if their tumors lack expression of wild-type KRAS. As allelic imbalance at the DNA level is not always reflective of the relative expression of the mutant or wild-type allele, these analyses may require a more sophisticated assessment at the RNA or protein level. To investigate this hypothesis, we evaluated the mutant to wildtype KRAS allelic frequency (AF) at the DNA and RNA level with in vitro drug sensitivities in a panel of cancer cell lines harboring KRAS mutations (NCBI SRA database). We observed no correlation between the relative mutant KRAS G12 (KRAS G12* ) AF at the DNA level with the IC 50 of MEK inhibitors trametinib and selumetinib in KRAS mutant cancer cell lines. In contrast, the relative KRAS mutant AF at the RNA level inversely correlated with the IC 50 for both trametinib and selumetinib (Figures S7E-S7J) . Moreover, the IC 50 values to MEK inhibitors were significantly lower in cell lines with a relative KRAS mutant AF of R0.7 (Figures S7K-S7N ). Given the challenges of reanalyzing prior clinical trials, future clinical studies of MEK inhibitors should evaluate and/or stratify patients based on the relative expression of wild-type and mutant KRAS alleles to determine their correlation with treatment outcome.
Additional studies will be required to determine how wild-type KRAS promotes resistance to MEK inhibition while simultaneously reducing the pool of active KRAS. Since both functions appear to depend on an intact dimer interface, we speculate that KRAS signaling dynamics may depend on the assembly of higher-order structures controlled by its dimerization at the cellular membrane. In this model, wild-type KRAS may function as the poisoning ''weakest link'' in a multi-protein complex that must remain intact for productive KRAS signaling. Such supramolecular complexes may have evolved to exert precise control over signal initiation/termination, convey threshold responses, and reduce biological noise under physiological conditions (Wu, 2013) . Clustering and dimerization-induced activation of downstream mediators, such as RAF, enhances temporal and spatial signaling control and might be key to integrating negative and positive feedback. Our observations on impaired feedback CRAF-S338 reactivation upon MEK inhibitor treatment in vivo in the presence of KRAS D154Q ( Figure 5A ), inefficient BRAF/ CRAF heterodimer formation, and CRAF activation in monomeric mutant KRAS (Figures 6 and 7 ) are in support of this model. One potential hypothesis is that in these dimers, wild-type KRAS may function as a molecular rheostat to stabilize MAPK signaling and to buffer perturbations in the system, such as MEK inhibition. Wild-type KRAS, in contrast to mutant KRAS, may still be responsive to upstream mitogenic stimuli ( Figure 2B ), thus further blunting the efficacy of MEK inhibitors. Thus, in KRAS mutant cancers, the tumor suppressive function of wild-type KRAS might be compensated by its ability to stabilize the signaling output. Recent studies have postulated that active KRAS dimers require two GTP-bound protomers (Muratcioglu et al., 2015; Nan et al., 2015) . It is possible that GTP-bound wild-type KRAS forms heterodimers with GTP-bound mutant KRAS but is more rapidly inactivated to the GDP-bound form because of either higher intrinsic or GAP-mediated GTP hydrolysis leading to destabilization of the entire signaling complex. An alternative explanation is that wild-type KRAS, when forming heterodimers with mutant KRAS, may directly influence the biochemical properties of the oncogene by increasing its GTPase activity and/or affecting its GDP/GTP exchange rate. Further genetic and biochemical studies are needed to understand which activity of a dimerization-proficient wild-type KRAS is necessary for it to exert these effects on mutant KRAS. Of note, this model is supported by our findings, showing an overall decrease in the cellular KRAS-GTP pool in both human and murine KRAS mutant LUAD cell lines upon the re-introduction of wild-type, but not the dimerization-impaired, KRAS
D154Q
( Figures S7O and S7P ).
Our studies also uncover a critical function for dimerization of oncogenic KRAS. Remarkably, the dimerization-deficient KRAS MUT/D154Q retains critical biochemical properties but lacks the biological properties of mutant KRAS (Figures 3, 6 , and 7). We demonstrate that oncogenic KRAS fails to support cell proliferation in vitro and in vivo in a GTP-bound monomeric state, possibly as a consequence of insufficient activation of MAPK signaling. Although the KRAS MUT/D154Q can still bind CRAF and recruit it to the membrane (Figures 3 and S4) , BRAF/CRAF dimerization is impaired ( Figure 6C ). How residual MAPK signaling is activated in the presence of reduced or impaired RAF dimerization remains to be determined. It is possible that despite the inability of KRAS to dimerize, the membrane localization (and as such, a high local concentration of monomeric KRAS bound to RAF) results in occasional RAF dimerization sufficient for low-level MAPK pathway activation. Additional studies will be required to further prove this hypothesis and to determine whether the residual MAPK activity can be further reduced with RAF or MEK inhibitors.
Collectively, our findings uncover a biologically critical but therapeutically exploitable role for KRAS dimerization. Given that KRAS is the most frequently mutated oncogene in human cancers, new treatment strategies are urgently needed. Not only may disruption of dimerization between wild-type and mutant KRAS enhance the efficacy of MEK inhibitors, but it may also be therapeutically effective by impairing the biological functions of oncogenic KRAS. Important additional questions raised by this work include whether KRAS4a and KRAS4b also undergo dimerization, whether different RAS isoforms can heterodimerize, and to what extent mutant-mutant dimers are favored over wild-type-mutant dimers. Recently, Spencer-Smith and colleagues (Spencer-Smith et al., 2017 ) developed a NS1 monobody, which modulates RAS-RAS interaction by interfering with the a4-a5 dimer interface. This and other strategies should be evaluated in future preclinical and ultimately clinical studies.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Models KRas +/LSLG12Vgeo (Guerra et al., 2003) , KRas lox/LSLG12Vgeo (Puyol et al., 2010) and p53 lox/lox (Jonkers et al., 2001 ) strains were bred in mixed genetic background and both males and females were used. Littermates were group housed, provided free access to standard diet and water, and were randomly assigned to experimental treatment groups. Tumors were induced in 8 to 12-weekold mice by single intra-tracheal AdCRE (Vector Core Iowa University) instillation with 1 3 10 6 pfu/mouse of virus after anesthesia (i.p. injection of ketamine 75 mg/kg, xylazine 12 mg/kg) as previously reported (Ambrogio et al., 2016 lung cancer cells (1 3 10 6 ) were injected intravenously into recipient mice. Selumetinib, solubilized in 1% carboxymethyl cellulose (CMC), 0.25% Tween 80 was administered daily by oral gavage (0.1 mL/10 g body weight) at a dose of 50 mg/kg in drug-naive mice. Animals randomly assigned to experimental treatment groups were dosed by oral gavage without blinding at any stage of the study. Welfare-related assessments and interventions were carried our daily during the treatment period. All care and treatment of experimental animals were in strict accordance with Good Animal Practice as defined by the US Office of Laboratory Animal Welfare and approved by the Dana-Farber Cancer Institute Institutional Animal Care and Use Committee.
Cell Line Authentication A549, H2122, SKLU1, H2030, H1792, H23, H358 and HEK293T cells were purchased from the ATCC and grown at 37 C in RPMI medium supplemented with 10% fetal bovine serum, 100 mg/ml penicillin and 100 units/ml streptomycin (complete medium lab and grown at 37 C in DMEM medium supplemented with 10% fetal bovine serum, 100 mg/ml penicillin and 100 units/ml streptomycin (complete medium) (Ambrogio et al., 2014; Drosten et al., 2010) . Human cell lines were authenticated in September 2015 using the Promega GenePrint 10 System at the RTSF Genomics Core at Michigan State University. All cell lines used in the study tested negative for Mycoplasma as determined by the Mycoplasma Plus PCR Primer Set (Agilent). Cell proliferation assays Cells (1 3 10 3 ) were seeded in 96-well plates in RPMI or DMEM complete medium. The following day, cells were treated with selumetinib or trametinib using a ten-point dose titration scheme from 1nM to 10 mM or from 1nM to 1 mM, respectively. After 72 hr, cell viability was assessed using colorimetric MTS assay (CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (MTS) Powder, Promega). Absolute inhibitory concentration (IC) values were calculated using four-parameter logistic curve fitting. All experimental points were a result of three to six replicates, and all experiments were repeated at least three times. The data was graphically displayed using GraphPad Prism 5 for Windows (GraphPad Software). Each point (mean ± standard deviation) represents growth of treated cells compared to untreated cells. The curves were fitted using a non-linear regression model with a sigmoidal dose response. Cells (1 3 10 3 ) were seeded in 96-well plates in 150 mL RPMI or DMEM complete medium. The following day, plates were incubated in the IncuCyte Zoom for real-time imaging, with three fields imaged per well under 10x magnification every two hours for a total of 60 to 96 hours. Data were analyzed using the IncuCyte Confluence version 1.5 software, which quantified cell surface area coverage as confluence values. IncuCyte experiments were performed in triplicate. A single representative growth curve is shown for each condition.
METHOD DETAILS
Growth Assessment by IncuCyte
Caspase-3/7 activity assay To measure apoptosis induction, 1 3 10 3 cells/well were labeled with 25 mM CellEvent caspase-3/7 green detection reagent (LifeTechnologies, Eugene, Oregon, USA) in RMPI or DMEM complete medium, treated as indicated and fluorescence was measured over time with IncuCyte technology (Essen BioScience) with an maximum absorption/emission of $502/530 nm.
Western Blot Analysis
Cells from in vitro culture or ex vivo explants were lysed in RIPA lysis buffer (#89900 Thermo Fisher) supplemented with protease and phosphatase inhibitor cocktail tablets (Roche). The antibodies used for western blotting included those against: KRAS (F234) (Santa Cruz Biotech Cat#sc-30), RAS (27H5) (Cell Signaling Cat#3339), HA-Tag (6E2) (Cell Signaling Cat#2367), HSP90 (H114) (Santa
